Intratumoral morphological heterogeneity of breast cancer: Neoadjuvant chemotherapy efficiency and multidrug resistance gene expression

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Denisov, Evgeny V ^a,b   Litviakov, Nikolay V ^a,b   Zavyalova, Marina V ^a,b,c   Perelmuter, Vladimir M ^a,c   Vtorushin, Sergey V ^a,c   Tsyganov, Matvey M ^a,b   Gerashchenko, Tatiana S ^a,b   Garbukov, Evgeny Yu ^a   Slonimskaya, Elena M ^a,c   Cherdyntseva, Nadezhda V ^a,b,c  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b TOMSK STATE UNIVERSITY   (Russian Federation)

^c SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCC5 PROTEIN, HUMAN; ABCG1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR PROTEIN;

ADJUVANT THERAPY; ADULT; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; P-GLYCOPROTEINS;

EID: 84898681404     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04709     Document Type: Article

References (48)

1. Bertos, N. R. &Park, M. Breast cancer - one term, many entities? J Clin Invest. 121, 3789-3796 (2011).
2. Ng, C. K. Pemberton, H. N. & Reis-Filho, J. S. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 12, 1021-1032 (2012).
3. Lakhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P. H. & van de Vijver, M. J. World Health Organization (WHO) classification of tumours of the breast, 4th ed (IARC Press, Lyon, 2012).
4. Tavassoli, F. A. & Devilee, P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (IARC Press, Lyon, 2003).
5. O'Malley, F. P., Pinder, S. E. &Mulligan, A. M. Breast Pathology, 2nd ed. (Elsevier, Philadelphia, 2011).
6. Goldschmidt, R. A. [Histopathology of malignant breast disease]. Atlas of clinical oncology. [Winchester, D. J. & Winchester, D. P. (eds.)]. [89-98] (B.C. Decker Inc., Hamilton, 2000).
7. Zavyalova, M. V. et al. The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis. Diagn Cytopathol. 41, 279-282 (2013).
8. Perelmuter, V. M. et al. Genetic and clinical and pathological characteristics of breast cancer in premenopausal and postmenopausal women. Adv Gerontol (Russian). 21, 643-653 (2008).
9. Zavyalova, M. V. et al. Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified. BioResearch Open Access. 2, 148-154 (2013).
10. Bhatia, S., Frangioni, J. V., Hoffman, R. M., Iafrate, A. J. & Polyak, K. The challenges posed by cancer heterogeneity. Nat Biotechnol. 30, 604-610 (2012).
11. Gerashchenko, T. S. et al. Intratumoral heterogeneity: nature and biological significance. Biochemistry (Mosc). 78, 1201-1215 (2013).
12. Zavyalova, M. V. et al. Relationship between tumor sensitivity to neoadjuvant chemotherapy and histologic pattern of primary tumor in unicentric infiltrating ductal breast carcinoma. Siberian Journal of Oncology. 6, 30-34 (2008).
13. Stavrovskaya, A. A. & Stromskaya, T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Moscow). 73, 592-604 (2008).
14. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu Rev Med. 53, 615-627 (2002).
15. Litviakov, N. V. et al. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemother Pharmacol. 71, 153-163 (2013).
16. Litviakov, N. V. et al. Connection of metastasis-free survival in breast cancer patients and an expression vector of multidrug resistance genes in tumor during neoadjuvant chemotherapy. Voprosy oncologii (Russ). 59, 334-340 (2013).
17. Kim, B. et al. Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One. 8, e62766 (2013).
18. Denisov, E., Tsyganov, M., Tashireva, L., Zavyalova, M., Perelmuter, V. & Cherdyntseva, N. Intratumoral heterogeneity in expression of chemotherapy response markers in invasive ductal breast carcinoma NOS. Paper presented at 4th WIN Symposium: Efficacy of biomarkers and personalized cancer therapeutics, Paris, France. Ann Oncol. 23, v21-v22 (2012).
19. Rafii, A. et al. Stromal cells extracted from ovarian cancer express functional multi drugs resistance proteins: ATP bindig casset and Major vault protein. Paper presented at ASCO Annual Meeting, Atlanta, USA. J Clin Oncol. 24, 2072 (2006).
20. Wishart, G. C. et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer. 62, 758-761 (1990).
21. Linn, S. C. et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer. 71, 787-795 (1997).
22. Sutherland, R. M., Eddy, H. A., Bareham, B., Reich, K. & Vanantwerp, D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys. 5, 1225-1230 (1979).
23. Durand, R. E. & Sutherland, R. M. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 71, 75-80 (1972).
24. Durand, R. E. Adriamycin: a possible indirect radiosensitizer of hypoxic tumor cells. Radiology. 119, 217-222 (1976).
25. Olive, P. L. & Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 13, 121-138 (1994).
26. Kobayashi, H., Man, S., Graham, C.H., Kapitain, S. J., Teicher, B. A. & Kerbel, R. S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A. 90, 3294-3298 (1993).
27. Desoize, B. & Jardillier, J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 36, 193-207 (2000).
28. Ivascu, A. & Kubbies, M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol. 31, 1403-1413 (2007).
29. Moore, N. & Lyle, S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011, (2011).
30. Mellor, H. R. & Callaghan, R. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemother Pharmacol. 68, 1179-1190 (2011).
31. Doublier, S. et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemoresistance of invasive micropapillary carcinoma of the breast. BMC Cancer. 12, 4 (2012).
32. Acs, G., Esposito, N. N., Rakosy, Z., Laronga, C. & Zhang, P. J. Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol. 34, 1637-1646 (2010).
33. Li, Y. S., Kaneko, M., Sakamoto, D. G., Takeshima, Y. & Inai, K. The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer. 13, 58-63 (2006).
34. Hou, J. M. et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 178, 989-996 (2011).
35. Yu, M., Stott, S., Toner, M., Maheswaran, S. & Haber, D. A. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 192, 373-382 (2011).
36. Stott, S. L. et al. Isolation of circulating tumor cells using amicrovortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 107, 18392-18397 (2010).
37. Brandt, B. et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 56, 4556-4561 (1996).
38. Kats-Ugurlu, G. et al. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol. 219, 287-293 (2009).
39. Murray, N. P., Vidal Albarran, R.-C., Pérez O, G., Ruiz M, A., Porcell E, J. & Castillo A, A. M. Cytomorphology of circulating tumor cells and cell clusters in Chilean patients with colo-rectal cancer. Int J Morphol. 30, 834-839 (2012).
40. Molnar, B., Ladanyi, A., Tanko, L., Sreter, L. & Tulassay, Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 7, 4080-4085 (2001).
41. Greene, B. T., Hughes, A. D. & King, M. R. Circulating tumor cells: the substrate of personalized medicine? Front Oncol. 2, 69 (2012).
42. Hou, J. M. et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 30, 525-532 (2012).
43. Hayward, J. L., Carbone, P. P., Heuson, J. C., Kumaoka, S., Segaloff, A. & Rubens, R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 39, 1289-1294 (1977).
44. Nishimura, M., Yoshitsugu, H., Naito, S. & Hiraoka, I. Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 122, 339-361 (2002).
45. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
46. Rice, W. R. Analyzing tables of statistical tests. Evolution. 43, 223-225 (1989).
47. Bender, R. & Lange, S. Adjusting for multiple testing-when and how? J Clin Epidemiol. 54, 343-349 (2001).
48. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131, 18-43 (2007).